What is Novocure Limited share price today?

Novocure Limited (NVCR) share price today is {{live_price}}.

Can Indians buy Novocure Limited shares?

Yes, Indians can invest in the Novocure Limited (NVCR) from India. With INDmoney, you can buy Novocure Limited at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Novocure Limited at zero transaction cost.

How can I buy Novocure Limited shares from India?

It is very easy to buy Novocure Limited from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novocure Limited be purchased?

Yes, you can buy fractional shares of Novocure Limited with INDmoney app.

What are the documents required to start investing in Novocure Limited stocks?

To start investing in Novocure Limited, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Novocure Limited

Today’s highest price of Novocure Limited (NVCR) is {{1_rba_end}}. Today’s lowest price of Novocure Limited (NVCR) is {{1_rba_st}}.

What is today's market capitalisation of Novocure Limited

Today's market capitalisation of Novocure Limited NVCR is 1.9B

What is the 52 Week High and Low Range of Novocure Limited

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Novocure Limited is down from its 52 Week High?

Novocure Limited (NVCR) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Novocure Limited is up from its 52 Week low?

Novocure Limited (NVCR) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Novocure Limited?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Novocure Limited

Mr. William F. Doyle is the current Chief Executive Officer (CEO) of Novocure Limited.

Home>
US Stocks>
Novocure Limited

Novocure Limited (NVCR)

$19.69

+1.81

(+10.12%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Novocure Limited Key Statistics

Market Capitalization	$1.9B
Revenue TTM	$577.7M
EBITDA	$-140.6M
Earnings Per Share (EPS)	$-1.39
Profit Margin	-25.93%
Quarterly Earnings Growth YOY	-0.06%
Return On Equity TTM	-39.71%

Novocure Limited share price movements

$18.30
$19.76
$19.69
7.06%
Downside
Day's Volatility :7.37%
Upside
0.33%
$11.66
$24.74
$19.69
40.78%
Downside
52 Weeks Volatility :52.86%
Upside
20.4%

Novocure Limited Returns

Period	Novocure Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	-0.3%	-5.9%	0.0%
6 Months	-10.54%	3.8%	0.0%
1 Year	59.43%	13.3%	0.0%
3 Years	-78.91%	11.0%	-21.1%

Analyst Recommendation on Novocure Limited

Buy

61%Buy

38%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Novocure Limited(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novocure Limited

What analysts predicted

Upside of 35.67%

Current $19.69

Target $26.71

Insights on Novocure Limited

Increasing Revenue
Revenue is up for the last 7 quarters, 122.18M → 155.09M (in $), with an average increase of 3.9% per quarter
Increasing Net Profit
Netprofit is up for the last 6 quarters, -57.41M → -30.57M (in $), with an average increase of 13.6% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 63.7% return, outperforming this stock by 4.3%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 135.2% return, outperforming this stock by 214.1%

Novocure Limited Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	248.1M	↑ 40.13%
Net Income	-63.6M	↑ 3.08%
Net Profit Margin	-25.62%	↑ 9.21%

	FY19	Y/Y Change
Revenue	351.3M	↑ 41.62%
Net Income	-7.2M	↓ 88.62%
Net Profit Margin	-2.06%	↑ 23.56%

	FY20	Y/Y Change
Revenue	494.4M	↑ 40.72%
Net Income	19.8M	↓ 373.97%
Net Profit Margin	4.01%	↑ 6.07%

	FY21	Y/Y Change
Revenue	535.0M	↑ 8.23%
Net Income	-58.4M	↓ 394.58%
Net Profit Margin	-10.91%	↓ 14.92%

	FY22	Y/Y Change
Revenue	537.8M	↑ 0.53%
Net Income	-92.5M	↑ 58.58%
Net Profit Margin	-17.2%	↓ 6.29%

	FY23	Y/Y Change
Revenue	509.3M	↓ 5.3%
Net Income	-207.0M	↑ 123.75%
Net Profit Margin	-40.65%	↓ 23.45%

	Q2 FY23	Q/Q Change
Revenue	126.1M	↑ 3.17%
Net Income	-57.4M	↑ 8.21%
Net Profit Margin	-45.55%	↓ 2.12%

	Q3 FY23	Q/Q Change
Revenue	127.3M	↑ 1.01%
Net Income	-49.5M	↓ 13.82%
Net Profit Margin	-38.87%	↑ 6.68%

	Q4 FY23	Q/Q Change
Revenue	133.8M	↑ 5.08%
Net Income	-47.1M	↓ 4.86%
Net Profit Margin	-35.19%	↑ 3.68%

	Q1 FY24	Q/Q Change
Revenue	138.5M	↑ 3.53%
Net Income	-38.8M	↓ 17.67%
Net Profit Margin	-27.98%	↑ 7.21%

	Q2 FY24	Q/Q Change
Revenue	150.4M	↑ 8.56%
Net Income	-33.4M	↓ 13.89%
Net Profit Margin	-22.2%	↑ 5.78%

	Q3 FY24	Q/Q Change
Revenue	155.1M	↑ 3.15%
Net Income	-30.6M	↓ 8.4%
Net Profit Margin	-19.71%	↑ 2.49%

	FY18	Y/Y Change
Total Assets	339.8M	↑ 28.08%
Total Liabilities	227.5M	↑ 49.96%

	FY19	Y/Y Change
Total Assets	479.4M	↑ 41.1%
Total Liabilities	261.7M	↑ 15.0%

	FY20	Y/Y Change
Total Assets	1.1B	↑ 119.42%
Total Liabilities	575.5M	↑ 119.93%

	FY21	Y/Y Change
Total Assets	1.1B	↑ 8.32%
Total Liabilities	729.0M	↑ 26.68%

	FY22	Y/Y Change
Total Assets	1.2B	↑ 4.58%
Total Liabilities	750.5M	↑ 2.95%

	FY23	Y/Y Change
Total Assets	1.1B	↓ 3.82%
Total Liabilities	783.6M	↑ 4.42%

	Q2 FY23	Q/Q Change
Total Assets	1.2B	↓ 1.3%
Total Liabilities	743.3M	↑ 0.15%

	Q3 FY23	Q/Q Change
Total Assets	1.1B	↓ 1.09%
Total Liabilities	752.6M	↑ 1.25%

	Q4 FY23	Q/Q Change
Total Assets	1.1B	↓ 0.02%
Total Liabilities	783.6M	↑ 4.12%

	Q1 FY24	Q/Q Change
Total Assets	1.1B	↓ 2.16%
Total Liabilities	762.1M	↓ 2.75%

	Q2 FY24	Q/Q Change
Total Assets	1.2B	↑ 8.09%
Total Liabilities	850.4M	↑ 11.59%

	Q3 FY24	Q/Q Change
Total Assets	1.2B	↑ 0.81%
Total Liabilities	861.2M	↑ 1.27%

	FY18	Y/Y Change
Operating Cash Flow	-1.9M	↓ 94.37%
Investing Cash Flow	-5.5M	↓ 163.66%
Financing Cash Flow	69.4M	↑ 1242.28%

	FY19	Y/Y Change
Operating Cash Flow	26.6M	↓ 1527.35%
Investing Cash Flow	-51.7M	↑ 840.6%
Financing Cash Flow	61.7M	↓ 11.08%

	FY20	Y/Y Change
Operating Cash Flow	99.1M	↑ 272.46%
Investing Cash Flow	-472.8M	↑ 815.18%
Financing Cash Flow	440.2M	↑ 613.69%

	FY21	Y/Y Change
Operating Cash Flow	82.8M	↓ 16.53%
Investing Cash Flow	-144.8M	↓ 69.37%
Financing Cash Flow	25.7M	↓ 94.16%

	FY22	Y/Y Change
Operating Cash Flow	30.8M	↓ 62.8%
Investing Cash Flow	-140.0M	↓ 3.37%
Financing Cash Flow	15.5M	↓ 39.73%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-22.7M	↑ 35.93%
Investing Cash Flow	-13.9M	↓ 116.89%
Financing Cash Flow	7.5M	↑ 44.16%

	Q3 FY23	Q/Q Change
Operating Cash Flow	-19.3M	↓ 15.05%
Investing Cash Flow	17.3M	↓ 224.19%
Financing Cash Flow	1.2M	↓ 84.39%

Novocure Limited Technicals Summary

Sell

Neutral

Buy

Novocure Limited is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Novocure Limited Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novocure Limited	16.58%	-10.54%	59.43%	-78.91%	-78.64%
Stryker Corporation	8.11%	13.78%	31.85%	59.4%	89.47%
Boston Scientific Corp.	7.32%	21.03%	63.69%	135.16%	109.83%
Edwards Lifesciences Corp.	3.89%	-17.19%	6.88%	-34.9%	-11.73%
Abbott Laboratories	4.89%	18.09%	14.78%	-7.09%	39.2%
Medtronic Plc	-4.48%	5.87%	9.4%	-21.77%	-22.55%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novocure Limited	NA	NA	-0.47	-1.31	-0.4	-0.08	NA	3.34
Stryker Corporation	41.65	41.65	2.72	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.39	74.39	1.64	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	27.83	27.83	6.56	2.53	0.19	0.11	NA	16.18
Abbott Laboratories	36.16	36.16	2.29	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novocure Limited	Buy	$1.9B	-78.64%	NA	-25.93%
Stryker Corporation	Buy	$148.0B	89.47%	41.65	16.34%
Boston Scientific Corp.	Buy	$133.8B	109.83%	74.39	11.26%
Edwards Lifesciences Corp.	Buy	$42.5B	-11.73%	27.83	65.86%
Abbott Laboratories	Buy	$206.3B	39.2%	36.16	13.99%
Medtronic Plc	Buy	$110.6B	-22.55%	26.38	12.06%

Novocure Limited Institutional Holdings

FMR Inc
15.00%
BlackRock Inc
11.21%
Vanguard Group Inc
10.95%
Capital Research & Mgmt Co - Division 3
7.32%
Capital World Investors
3.98%
Nordwand Advisors LLC
2.80%

Corporate Announcements

Novocure Limited Earnings
Novocure Limited’s price-to-earnings ratio stands at None
Read More

About Novocure Limited

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Organization	Novocure Limited
Employees	1453
CEO	Mr. William F. Doyle
Industry	Health Technology

Novocure Limited (NVCR)

Novocure Limited Key Statistics

Novocure Limited share price movements

Novocure Limited Returns

Analyst Recommendation on Novocure Limited

Analyst Forecast on Novocure Limited

Increasing Revenue

Increasing Net Profit

Vs BSX